- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03395288
Nutraceutical Efficacy for rUTI
Randomized, Controlled Trial to Determine the Efficacy of Nutraceutical vs Control as Non-antibiotic Prophylaxis for Recurrent Urinary Tract Infection in Postmenopausal Women Using Vaginal Estrogen Therapy
Study Overview
Detailed Description
The objective of this study is to determine the efficacy of a nutraceutical as a non-antibiotic prophylaxis for postmenopausal women on vaginal estrogen therapy (VET) with a history of symptomatic, culture-proven recurrent urinary tract infection (rUTI) by means of a randomized, controlled trial. Recurrent urinary tract infections have a significant impact on patient health, quality of life, and finances (personal and societal).
The most common uropathogen for both acute and recurrent UTIs is Escherichia coli.
Historically, patients with rUTI have been placed on long-term prophylactic antibiotics to prevent recurrence. Long term antibiotic use can lead to antibiotic resistance, collateral damage to normal flora, and organ damage, such as pulmonary and hepatic toxicity with long-term nitrofurantoin use. There is an increasing prevalence of antibiotic resistance of uropathogenic E. coli and other uropathogens. Antibiotic resistance and its consequences have resulted in a need for non-antibiotic prophylaxis regimens.
A growing body of literature supports the use of vaginal estrogen therapy as a first-line non-antibiotic UTI prevention strategy in postmenopausal women. While VET has been shown to significantly reduce the risk of rUTIs, some women continue to have rUTIs. Other non-antibiotic strategies have been utilized including D-mannose, a nutraceutical. Three prior studies examined D-mannose as an isolated therapy with promising results, but in our experience, a multimodal approach has often been needed. Therefore, additional studies, such as this proposed research, are needed to determine the potential additive effect of a nutraceutical as a non-antibiotic prophylaxis for postmenopausal women using vaginal estrogen therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For the RCT arms of the study, the following inclusion criteria will apply:
a. Postmenopausal women with recurrent UTI
i. Recurrent UTI defined as:
- ≥ 2 symptomatic, culture-proven UTI in 6 months OR
≥ 3 symptomatic, culture-proven UTI in 12 months
ii. Postmenopausal defined as no menses for at least 12 months or surgical menopause
b. At least one documented prior uropathogen susceptible to D-mannose
c. Using VET for a minimum of four weeks prior to study day 1
Inclusion criteria for the Observational arm of the study are the same with the exception of item 'c.' above (using VET for a minimum of four weeks) as participants will not be on vaginal estrogen therapy.
Exclusion Criteria:
For the RCT arms of the study, the exclusion criteria are as follows:
- Not postmenopausal
- Currently on daily antibiotic UTI prophylaxis (If this is the only exclusion criteria met, a woman could be cleared for inclusion in study/enrollment after a 2 week washout period occurs prior to inclusion in the study (RCT or Observational arm))
- Complicated UTIs (known renal tract anomaly, inability to empty bladder due to neurologic causes, performs self-catheterization or has an indwelling catheter)
- Patients with incomplete bladder emptying (defined as post void residual > 150 cc when minimal voided volume is >150 cc)
- Known contraindication to VET unless approved by patient's oncologist, oncologic surgeon, or primary care physician (History of or current endometrial cancer; History of estrogen sensitive breast cancer without approval of patient, patient's oncologist, oncologic surgeon, or primary care physician to use vaginal estrogen after counseling)
- History of interstitial cystitis/painful bladder syndrome
- Urothelial cancer
- Non-English speaking
- Enrolled in other clinical trials for UTIs
- Currently using D-mannose or Methenamine for UTI prevention
Exclusion criteria for the Observational arm of the study are the same with the exception of item 'e.' above (known contraindication to VET) as participants will not be on vaginal estrogen therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RCT treatment arm
Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours.
(200 ml of water = 6.7 fluid ounces).
Duration of study drug is 90 days.
|
A total of 2 g D-mannose daily
|
No Intervention: RCT control arm
Participants in this arm will not use any additional intervention.
|
|
Experimental: Observational arm
Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours.
(200 ml of water = 6.7 fluid ounces).
Duration of study drug is 90 days.
Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
|
A total of 2 g D-mannose daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Symptomatic, Culture Proven Urinary Tract Infections
Time Frame: each participant will be followed for 90 days during study enrollment
|
To compare the cumulative incidence of symptomatic, culture-proven urinary tract infections in postmenopausal women with a history of rUTI on vaginal estrogen therapy randomized to receive prophylactic D-mannose versus women using vaginal estrogen therapy alone (control).
|
each participant will be followed for 90 days during study enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Symptomatic Culture Proved UTI From D-mannose Susceptible Uropathogens
Time Frame: each participant will be followed for 90 days during study enrollment
|
To compare the incidence of symptomatic, culture-proven urinary tract infections caused by all uropathogens potentially susceptible to D-mannose therapy in women receiving D-mannose and the control group.
We will also compare these findings to the incidence of symptomatic, culture-proven urinary tract infections caused by uropathogens susceptible to D-mannose therapy in the absence of vaginal estrogen therapy (Control Arm).
|
each participant will be followed for 90 days during study enrollment
|
Side Effects
Time Frame: each participant will be followed for 90 days during study enrollment
|
To describe the side effects of D-mannose and determine the incidence of discontinuation of therapy due to side effects.
|
each participant will be followed for 90 days during study enrollment
|
Incidence of Symptomatic, Culture Proven UTI in All Participants Taking D-mannose
Time Frame: each participant will be followed for 90 days during study enrollment
|
To compare the cumulative incidence of symptomatic, culture-proven urinary tract infections between women receiving prophylactic D-mannose treatment alongside vaginal estrogen therapy verses women receiving prophylactic D-mannose treatment whom are not on vaginal estrogen therapy (observational arm).
|
each participant will be followed for 90 days during study enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jerry Lowder, MD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201711120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
Newcastle-upon-Tyne Hospitals NHS TrustCambridge University Hospitals NHS Foundation Trust; University of Southampton and other collaboratorsCompletedUrinary Tract Infections, RecurrentUnited Kingdom
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Hospital del Río HortegaCompletedUrinary Tract Infection
-
Assaf-Harofeh Medical CenterNanovibronixUnknown
-
Bergaliden BarnavårdscentralCompleted
Clinical Trials on D-Mannose
-
University College, LondonUCLHUnknownMultiple Sclerosis | Recurrent Urinary Tract InfectionsUnited Kingdom
-
Kantonsspital AarauTerminatedUrinary Tract InfectionsSwitzerland
-
RenovoCompleted
-
RenovoCompletedCicatrix | Re-epithelialisationUnited Kingdom
-
RenovoCompletedCicatrix | Wound-healingUnited Kingdom
-
University of Colorado, DenverTerminatedPregnancy | IUGRUnited States
-
Peking University Third HospitalRecruiting
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedUrinary Tract Infections, RecurrentItaly